These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 18215142

  • 1. The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning.
    Golubovskaya VM, Finch R, Zheng M, Kurenova EV, Cance WG.
    Biochem J; 2008 Apr 01; 411(1):151-60. PubMed ID: 18215142
    [Abstract] [Full Text] [Related]

  • 2. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z.
    J Mol Biol; 2009 Jan 09; 385(1):249-65. PubMed ID: 18996393
    [Abstract] [Full Text] [Related]

  • 3. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
    Garces CA, Kurenova EV, Golubovskaya VM, Cance WG.
    Cancer Res; 2006 Feb 01; 66(3):1446-54. PubMed ID: 16452200
    [Abstract] [Full Text] [Related]

  • 4. Role of p53/FAK association and p53Ser46 phosphorylation in staurosporine-mediated apoptosis: wild type versus mutant p53-R175H.
    Fanucchi S, Veale RB.
    FEBS Lett; 2009 Nov 19; 583(22):3557-62. PubMed ID: 19857493
    [Abstract] [Full Text] [Related]

  • 5. p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress.
    Jiang M, Axe T, Holgate R, Rubbi CP, Okorokov AL, Mee T, Milner J.
    Oncogene; 2001 Sep 06; 20(39):5449-58. PubMed ID: 11571642
    [Abstract] [Full Text] [Related]

  • 6. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions.
    Edwards SJ, Hananeia L, Eccles MR, Zhang YF, Braithwaite AW.
    Oncogene; 2003 Jul 17; 22(29):4517-23. PubMed ID: 12881708
    [Abstract] [Full Text] [Related]

  • 7. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.
    Lin J, Teresky AK, Levine AJ.
    Oncogene; 1995 Jun 15; 10(12):2387-90. PubMed ID: 7784087
    [Abstract] [Full Text] [Related]

  • 8. The prolyl cis/trans isomerase cyclophilin 18 interacts with the tumor suppressor p53 and modifies its functions in cell cycle regulation and apoptosis.
    Baum N, Schiene-Fischer C, Frost M, Schumann M, Sabapathy K, Ohlenschläger O, Grosse F, Schlott B.
    Oncogene; 2009 Nov 05; 28(44):3915-25. PubMed ID: 19718045
    [Abstract] [Full Text] [Related]

  • 9. C-terminal peptides of p53 molecules enhance radiation-induced apoptosis in human mutant p53 cancer cells.
    Ohnishi K, Inaba H, Yasumoto J, Yuki K, Takahashi A, Ohnishi T.
    Apoptosis; 2004 Sep 05; 9(5):591-7. PubMed ID: 15314287
    [Abstract] [Full Text] [Related]

  • 10. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity.
    Zhu J, Jiang J, Zhou W, Zhu K, Chen X.
    Oncogene; 1999 Mar 25; 18(12):2149-55. PubMed ID: 10321740
    [Abstract] [Full Text] [Related]

  • 11. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines.
    Blanco S, Klimcakova L, Vega FM, Lazo PA.
    FEBS J; 2006 Jun 25; 273(11):2487-504. PubMed ID: 16704422
    [Abstract] [Full Text] [Related]

  • 12. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
    Quaresima B, Faniello MC, Baudi F, Crugliano T, Di Sanzo M, Cuda G, Costanzo F, Venuta S.
    Oncol Rep; 2006 Oct 25; 16(4):811-5. PubMed ID: 16969499
    [Abstract] [Full Text] [Related]

  • 13. Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53.
    Golubovskaya VM, Finch R, Cance WG.
    J Biol Chem; 2005 Jul 01; 280(26):25008-21. PubMed ID: 15855171
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The interaction of the hnRNP family member E1B-AP5 with p53.
    Barral PM, Rusch A, Turnell AS, Gallimore PH, Byrd PJ, Dobner T, Grand RJ.
    FEBS Lett; 2005 May 23; 579(13):2752-8. PubMed ID: 15907477
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.
    Xu H, Tai J, Ye H, Kang CB, Yoon HS.
    Biochem Biophys Res Commun; 2006 Mar 24; 341(4):938-44. PubMed ID: 16455050
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.
    Trulson JA, Millhauser GL.
    Biopolymers; 1999 Mar 24; 49(3):215-24. PubMed ID: 9990839
    [Abstract] [Full Text] [Related]

  • 20. Identification of a novel isoform of iASPP and its interaction with p53.
    Zhang X, Diao S, Rao Q, Xing H, Liu H, Liao X, Wang M, Wang J.
    J Mol Biol; 2007 May 11; 368(4):1162-71. PubMed ID: 17391696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.